Related Experiment Video

Updated: May 13, 2026

An In Ovo Model for Testing Insulin-mimetic Compounds
06:09

An In Ovo Model for Testing Insulin-mimetic Compounds

Published on: April 23, 2018

A novel insulin mimetic vanadium-flavonol complex: synthesis, characterization and in vivo evaluation in STZ-induced

Subramanian Iyyam Pillai1, Sorimuthu Pillai Subramanian, Muthusamy Kandaswamy

  • 1Department of Inorganic Chemistry, University of Madras, Guindy Campus, Chennai 600 025, Tamil Nadu, India.

European Journal of Medicinal Chemistry
|March 8, 2013
PubMed

Insights

Researchers developed a novel vanadium-flavonol complex to treat diabetes. This non-toxic compound effectively lowers blood glucose levels in diabetic rats, offering a promising alternative to traditional vanadium therapies.

Area of Science:

  • Biochemistry
  • Pharmacology
  • Toxicology

Background:

  • Vanadium compounds show anti-diabetic and insulinomimetic potential, first observed in 1985.
  • Concerns regarding chronic toxicity and vanadium accumulation have hindered clinical acceptance.
  • A novel approach is needed to harness vanadium's benefits while mitigating risks.

Purpose of the Study:

  • To synthesize and characterize a novel vanadium-flavonol complex.
  • To evaluate the toxicological profile of this complex.
  • To assess its anti-diabetic and insulin mimetic potential in experimental diabetes.

Main Methods:

  • Synthesis and characterization of a new vanadium-flavonol complex.
  • Toxicological evaluation in a rat model.
  • Assessment of anti-diabetic activity in streptozotocin-induced diabetic rats.

Main Results:

  • The synthesized vanadium-flavonol complex demonstrated non-toxicity.
  • The complex exhibited significant anti-diabetic activity.
  • Insulin mimetic potential was observed, suggesting therapeutic efficacy.

Conclusions:

  • The novel vanadium-flavonol complex is non-toxic and possesses anti-diabetic properties.
  • This complex represents a promising therapeutic strategy for managing diabetes.
  • Further research into vanadium-flavonol complexes could lead to safer anti-diabetic treatments.

More Related Videos

An Ultrasonic Tool for Nerve Conduction Block in Diabetic Rat Models10:27

An Ultrasonic Tool for Nerve Conduction Block in Diabetic Rat Models

Published on: October 20, 2017

A Protocol for Constructing a Rat Wound Model of Type 1 Diabetes05:18

A Protocol for Constructing a Rat Wound Model of Type 1 Diabetes

Published on: February 17, 2023

Related Concept Videos

Insulin: Biosynthesis, Chemistry, and Preparation01:25

Insulin: Biosynthesis, Chemistry, and Preparation

The endoplasmic reticulum (ER) of pancreatic β-cells synthesizes preproinsulin, which consists of a signal peptide, A and B chains, and a C-peptide. Preproinsulin is then cleaved and folded into proinsulin, which translocates to the Golgi apparatus for sorting and packaging into secretory granules. In these granules, enzymatic clipping generates insulin and C-peptide.
Damage or functional impairment of β-cells inhibits insulin production, leading to diabetes. Diabetes treatment primarily uses...
Oral Hypoglycemic Agents: Biguanides and Glitazones01:26

Oral Hypoglycemic Agents: Biguanides and Glitazones

Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood glucose levels...
Diabetes Mellitus: Introduction01:26

Diabetes Mellitus: Introduction

Diabetes mellitus consists of chronic metabolic disorders characterized by persistent hyperglycemia. This elevated blood glucose results from defects in insulin secretion, impaired insulin action, or both. Insulin, produced by pancreatic β-cells, is essential for maintaining glucose homeostasis by facilitating cellular glucose uptake for energy or storage. Disruptions in insulin production or function lead to glucose accumulation in the bloodstream, causing the clinical features and long-term...
Glucagon-like Receptor Agonists01:24

Glucagon-like Receptor Agonists

Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by the...
Type II Diabetes II: Pathophysiology01:24

Type II Diabetes II: Pathophysiology

PathophysiologyType 2 diabetes mellitus (T2DM ) is a chronic metabolic disorder characterized by insulin resistance and progressive pancreatic β-cell dysfunction, leading to impaired glucose homeostasis. It results from interactions among genetic predisposition, environmental factors, and metabolic stressors, such as overnutrition and a sedentary lifestyle.Insulin Resistance and Glucose DysregulationEarly T2DM involves insulin resistance in skeletal muscle, adipose tissue, and the liver.
Type II Diabetes Mellitus III: Clinical Manifestations and Diagnosis01:25

Type II Diabetes Mellitus III: Clinical Manifestations and Diagnosis

Type 2 diabetes mellitus develops gradually and is often asymptomatic in early stages.Clinical ManifestationsWhen symptoms appear, they include fatigue, blurred vision, pruritus, delayed wound healing, and recurrent infections, particularly candidal infections. Peripheral neuropathy may present as numbness or tingling in the extremities. Classic hyperglycemia symptoms—polyuria, polydipsia, and polyphagia—are less common. Most patients are overweight and frequently have associated hypertension...